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ABSTRACT
Introduction: Canagliflozin, a sodium glucose
co-transporter 2 (SGLT2) inhibitor, has
demonstrated sustained improvements in
glycemic control and body weight reductions
with treatment for up to 104 weeks in a broad
range of patients with type 2 diabetes mellitus
(T2DM).
Methods: This was a post hoc analysis of
individual patient data (N = 1450) from a
randomized, double-blind, placebo-controlled,
Phase 3 study comparing canagliflozin with
glimepiride as add-on to metformin in patients
with T2DM during a 52-week core period
followed by a 52-week extension period. The
number of patients who achieved a reduction
from baseline in both HbA1c and body weight
with canagliflozin 100 and 300 mg and
glimepiride was assessed at Weeks 52 and 104.
Safety was recorded as adverse events (AEs)
during the study.
Results: Canagliflozin 100 and 300 mg
provided durable glycemic improvements and
body weight reductions compared with
glimepiride over 104 weeks. At Week 52, the
proportion of patients who achieved reductions
in both HbA1c and body weight was 72.4% with
canagliflozin 100 mg, 78.5% with canagliflozin
300 mg, and 26.8% with glimepiride; similar
results were observed at Week 104 (65.5%,
71.1%, and 26.8% with canagliflozin 100 and
300 mg and glimepiride, respectively). The AE
profile of canagliflozin was comparable to that
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observed in previous studies, with increased
incidence of AEs related to the mechanism of
SGLT2 inhibition (e.g., genital mycotic
infections, urinary tract infections, and
osmotic diuresis–related AEs) and a low risk of
hypoglycemia.
Conclusion: More patients treated with
canagliflozin experienced reductions in both
HbA1c and body weight compared with
glimepiride for up to 104 weeks. Canagliflozin
was generally well tolerated in patients with
T2DM when used in combination with
metformin.
Clinical Trial Registration: ClinicalTrials.gov
identifier, NCT00968812.
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INTRODUCTION
Current guidelines for the management of type 2
diabetes mellitus (T2DM) routinely recommend
metformin as first-line therapy in those who are
able to tolerate this agent [1]. However, there are
numerous options for second-line therapies for
use in combination with metformin in
individuals unlikely to achieve their target
HbA1c levels with metformin alone. Among
these, sulfonylureas are a well-established drug
class, but they are typically associated with
weight gain and hypoglycemia [1, 2]. Many
patients with T2DM are overweight or obese,
and further increases in body weight may be
detrimental to their well-being, particularly
increasing the risk of cardiovascular disease and
microvascular disease [3].
Sodium glucose co-transporter 2 (SGLT2)
inhibitors are another therapeutic class
recommended in current guidelines as an
option for combination therapy with
metformin and are associated with weight loss
and a low risk of hypoglycemia [1].
Canagliflozin is an SGLT2 inhibitor approved
for the treatment of adults with T2DM [4].
Canagliflozin reduces plasma glucose levels by
lowering the renal threshold for glucose,
thereby increasing urinary glucose excretion
[5, 6]. In a head-to-head study of canagliflozin
versus the sulfonylurea glimepiride as add-on to
metformin in patients with T2DM, canagliflozin
has demonstrated sustained improvements in
glycemic control, together with sustained
reductions in body weight, over 104 weeks [7,
8].
In addition to measuring HbA1c in patients
with T2DM, there is increasing recognition of
the value of using composite endpoints to
evaluate T2DM treatments [9]. Since glycemic
control and weight loss are beneficial for most
patients with T2DM, this post hoc analysis
evaluated the effect of canagliflozin versus
glimepiride on reducing both HbA1c and body
weight in patients with T2DM inadequately




This post hoc analysis was based on data from a
104-week, randomized, double-blind,
active-controlled, non-inferiority, Phase 3
study in patients with T2DM inadequately
controlled on metformin. Patients were
randomized 1:1:1 to one of the following
once-daily treatments: canagliflozin 100 mg,
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canagliflozin 300 mg, or glimepiride (titrated to
a maximum of 6 or 8 mg). The study was
conducted at 157 study centers in 19 countries
and consisted of a 52-week, double-blind core
treatment period, followed by a 52-week,
double-blind extension period. Details of the
study design have been reported previously [7,
8].
Briefly, patients were required to be aged
18–80 years and to have inadequately
controlled T2DM (HbA1c between 7.0% and
9.5%) while receiving metformin at stable doses
of C2000 mg/day (or C1500 mg/day if unable to
tolerate higher doses) for at least 10 weeks.
Exclusion criteria included a history of type 1
diabetes; a history of more than one severe
hypoglycemia episode (within 6 months);
repeated measurements of fasting plasma
glucose or fasting self-monitored blood glucose
of C15.0 mmol/L during the pre-treatment
phase; an estimated glomerular filtration rate of
\55 mL/min/1.73 m2 (or \60 mL/min/1.73 m2
if based on restriction of metformin use in local
label) or serum creatinine concentrations of
C124 lmol/L for men and C115 lmol/L for
women; or were taking thiazolidinediones
within 16 weeks before screening. Patients were
not permitted to use any antihyperglycemic
agents, except for metformin, unless
pioglitazone was prescribed for rescue therapy.
Use of insulin for C3 continuous or 7 total days
within 3 months of screening was not
permitted; however, insulin could be used on
up to 2 occasions for no more than 7
consecutive days during the study.
Endpoints
Change in HbA1c and percent change in body
weight from baseline were pre-specified study
endpoints. Using individual patient data, the
proportion of patients who achieved a decrease
from baseline in both HbA1c (%) and body
weight (kg) was assessed at Weeks 52 and 104.
Safety was assessed based on adverse event (AE)
reports. Documented hypoglycemia episodes
included biochemically documented episodes
(concurrent fingerstick glucose or plasma
glucose B3.9 mmol/L with or without
symptoms) and severe episodes (i.e., requiring
the assistance of another individual or resulting
in seizure or loss of consciousness).
Statistical Analyses
Analyses were performed using the modified
intent-to-treat (mITT) population, which
consisted of all randomized patients who
received C1 dose of study drug. The last
observation carried forward (LOCF) approach
was used to impute missing data. Efficacy
endpoints were analyzed using an analysis of
covariance (ANCOVA) model, with treatment,
stratification factors, and country as fixed
effects and the corresponding baseline value as
a covariate.
The least squares (LS) mean differences
between groups and 2-sided 95% confidence
intervals (CIs) were estimated for changes in
HbA1c and body weight and for the proportion
of patients achieving reductions in both HbA1c
and body weight. Odds ratios (ORs) and 95%
CIs for the achievement of reductions in both
HbA1c and body weight were also estimated.
P values are reported for the prespecified
comparison of percent change in body weight
with canagliflozin versus glimepiride at Week
52 only. Statistical testing was not prespecified
for efficacy comparisons at Week 104 or for the
post hoc composite endpoint analyses;
therefore, no P values are reported. Statistical
analyses were performed using SAS, version 9.2
(Cary, NC, USA).
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Compliance with Ethics
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all




A total of 1450 subjects comprised the mITT
and safety analysis sets; 71.0%, 66.6%, and
65.1% completed the 104-week, double-blind
treatment period with canagliflozin 100 and
300 mg and glimepiride, respectively [8].
Baseline demographic and disease
characteristics were comparable across
treatment groups, with a mean age of
56.2 years, HbA1c of 7.8%, and body mass
index (BMI) of 31.0 kg/m2 (Table 1). Mean
metformin dose was 2177 mg/day; 62% of
patients were taking metformin immediate
release and 38% were taking metformin
extended release. Among patients in the
glimepiride group, 91.3% uptitrated over
104 weeks, with a mean maximum glimepiride
dose of 5.8 mg and a mean final dose of 5.6 mg.
Approximately 54% of subjects were considered
to be obese (BMI C30 kg/m2), based upon
National Institutes of Health criteria [10].
Efficacy
Across all groups, there was a reduction from
baseline in HbA1c at 52 and 104 weeks
(Table 2). The nadir in HbA1c was reached at
Week 52 in both canagliflozin groups, with
small increases thereafter; for glimepiride, the
nadir in HbA1c was reached at Week 18, with a
subsequent continual rise through Week 104
[8]. Body weight decreased over 52 weeks and
then remained stable through Week 104 in both
canagliflozin groups, while body weight
increased over 52 weeks in the glimepiride
group and then remained stable through
Week 104 (Table 2) [8].
At Week 52, 72.4%, 78.5%, and 26.8% of
patients achieved reductions in both HbA1c and
body weight with canagliflozin 100 and 300 mg
versus glimepiride, respectively (Fig. 1; Table 3).
Odds for achieving this composite endpoint
favored canagliflozin 100 and 300 mg versus
glimepiride [ORs (95% CI) of 7.7 (5.7, 10.3) and
10.7 (7.9, 14.5), respectively]. At Week 104,
65.5%, 71.1%, and 26.8% of patients achieved
reductions in both HbA1c and body weight
with canagliflozin 100 and 300 mg and
glimepiride, respectively (Fig. 2; Table 3). Odds
for achieving this composite endpoint favored
canagliflozin 100 and 300 mg versus
glimepiride [ORs (95% CI) of 5.6 (4.2, 7.5) and
7.4 (5.5, 9.8), respectively].
Safety
Details of the safety of canagliflozin 100 and
300 mg versus glimepiride over 104 weeks have
been previously reported [8]. Briefly, the overall
incidence of AEs was 73.3%, 77.9%, and 78.4%
with canagliflozin 100 and 300 mg and
glimepiride, respectively; the incidence of AEs
leading to discontinuation was 6.2%, 9.5%, and
7.3%, respectively, and the incidence of serious
AEs was 9.7%, 9.7%, and 14.3%, respectively.
Incidences of genital mycotic infections in men
(9.5% and 9.1% vs 1.9%) and women (13.9%
and 15.6% vs 2.7%), urinary tract infections
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Male 263 (55) 252 (52) 241 (50)
Female 219 (45) 231 (48) 244 (50)
Mean ± SD age (years) 56.3 ± 9.0 56.4 ± 9.5 55.8 ± 9.2
Race, n (%)
White 322 (67) 323 (67) 333 (69)
Black/African American 22 (5) 20 (4) 18 (4)
Asian 93 (19) 99 (21) 93 (19)
Othera 45 (9) 41 (8) 41 (8)
Mean ± SD body weight (kg) 86.5 ± 19.8 86.9 ± 20.1 86.6 ± 19.5
Mean ± SD body mass index (kg/m2) 30.9 ± 5.5 31.0 ± 5.3 31.2 ± 5.4
Mean ± SD HbA1c (%) 7.8 ± 0.8 7.8 ± 0.8 7.8 ± 0.8
Mean ± SD duration of T2DM (years) 6.6 ± 5.0 6.5 ± 5.5 6.7 ± 5.5
CANA canagliﬂozin, GLIM glimepiride, SD standard deviation, T2DM type 2 diabetes mellitus
a Includes American Indian or Alaska Native, Native Hawaiian or other Paciﬁc Islander, multiple, and other
Table 2 Summary of changes in HbA1c and body weight at Weeks 52 and 104









LS mean change in HbA1c (%) –0.81 –0.82 –0.93 –0.55 –0.65 –0.74








LS mean % change in
body weight
1.0 –4.2 –4.7 0.9 –4.1 –4.2








LS mean change in
body weight (kg)
0.7 –3.7 –4.0 0.8 –3.6 –3.6








CANA canagliﬂozin, CI conﬁdence interval, GLIM glimepiride, LS least squares
a P\0.001 vs GLIM
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(10.6% and 8.7% vs 6.8%), and AEs related to
osmotic diuresis (5.8% and 6.6% vs 2.1%) were
higher with canagliflozin 100 and 300 mg
versus glimepiride. At Week 104, the incidence
of documented hypoglycemia was lower with
canagliflozin 100 and 300 mg versus
glimepiride (6.8% and 8.2% vs 40.9%). The
frequency of severe hypoglycemic episodes was
0.6% (n = 3), 0.2% (n = 1), and 3.3% (n = 16)
with canagliflozin 100 and 300 mg and
glimepiride, respectively.
DISCUSSION
In this post hoc analysis, patients with T2DM
inadequately controlled with metformin who
were treated with canagliflozin were more likely
to achieve improved glycemic control (as
evidenced by lower HbA1c) and concomitant
weight loss than those treated with glimepiride
at 52 and 104 weeks. Canagliflozin was well
tolerated with an AE profile comparable to that
previously documented in other studies,
including increased incidence of genital
mycotic infections, urinary tract infections,
and AEs related to osmotic diuresis [4]. In
addition, canagliflozin was associated with
lower rates of hypoglycemia compared with
glimepiride, including a low risk of severe
episodes, over 104 weeks.
Glycemic improvements, weight loss, and
low risk of hypoglycemia have also been
reported with the SGLT2 inhibitors
dapagliflozin and empagliflozin in patients
with T2DM on background metformin versus
sulfonylurea [11–14]. Composite endpoint
analyses of reduction in both HbA1c and body
weight have been reported with dapagliflozin,
but not empagliflozin, and results were
generally consistent with the present study. In
a 52-week study of dapagliflozin versus glipizide
as add-on to metformin, a higher proportion of
patients achieved reductions in both HbA1c and
body weight with dapagliflozin versus glipizide
(66.9% vs 21.3%) [15]. Overall, findings with
canagliflozin and dapagliflozin demonstrate
that SGLT2 inhibitors may provide better
Fig. 1 Change in both HbA1c and body weight with
a CANA 100 mg and b CANA 300 mg versus GLIM at
Week 52. CANA canagliﬂozin, GLIM glimepiride
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achievement of both HbA1c and weight loss
compared with sulfonylureas in patients with
T2DM.
A previous study suggested that *40% of
patients with T2DM who are receiving
metformin monotherapy and add a
sulfonylurea to their treatment regimen will
gain weight in the year following
intensification of therapy [3]. Additionally,
with every increase in BMI category (from
normal to severely obese), the rate of
hospitalizations for cardiovascular disease,
stroke, amputation, blindness, and end-stage
renal disease rose [3]. Thus, in addition to
improvements in glycemic control, the
reductions in body weight provided by
canagliflozin make it a promising treatment
option for patients with T2DM who are
overweight or obese. The benefits of weight
loss on other diabetes-related outcomes with
canagliflozin have been demonstrated in an
analysis of pooled data from 4 randomized,
double-blind, placebo-controlled trials in which
*15% of HbA1c lowering and*40% of systolic
blood pressure lowering was associated with
weight loss; thus, each 1% reduction in body
weight was associated with a 0.045% decrease
in HbA1c and a 0.62 mmHg reduction in
systolic blood pressure [16]. Indeed, a
reduction of 5–10% in body weight in patients
with T2DM is associated with beneficial effects
on glycemia, blood pressure, high-density
lipoprotein cholesterol (HDL-C), and
triglycerides [17]. However, it is unknown
whether these benefits will translate to
improvement in long-term clinical outcomes,
including cardiovascular disease. Patients with
T2DM with pre-existing cardiovascular disease
who had reductions in HbA1c, body weight,
and blood pressure with the SGLT2 inhibitor
empagliflozin were shown to have decreased
risk of cardiovascular events and mortality [18].
The ongoing CANagliflozin cardioVascular
Assessment Study (CANVAS; ClinicalTrials.gov
Identifier: NCT01032629) and CANVAS-R (renal
endpoints; NCT01989754) trials will evaluate
the long-term efficacy and safety, including
cardiovascular outcomes, of canagliflozin in
patients with T2DM and a history or high risk
of cardiovascular disease [19].
Table 3 Proportion of patients with both HbA1c and body weight reduction at Weeks 52 and 104
GLIM (n5 474) CANA 100 mg (n 5 478) CANA 300 mg (n5 474)
Week 52
Patients, n (%) 127 (26.8) 346 (72.4) 372 (78.5)
Difference vs GLIM (95% CI) 45.6 (39.7, 51.5) 51.7 (46.0, 57.3)
OR vs GLIM (95% CI) 7.7 (5.7, 10.3) 10.7 (7.9, 14.5)
Week 104
Patients, n (%) 127 (26.8) 313 (65.5) 337 (71.1)
Difference vs GLIM (95% CI) 38.7 (32.6, 44.7) 44.3 (38.4, 50.2)
OR vs GLIM (95% CI) 5.6 (4.2, 7.5) 7.4 (5.5, 9.8)
CANA canagliﬂozin, CI conﬁdence interval, GLIM glimepiride, OR odds ratio
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CONCLUSION
In summary, canagliflozin provided greater
attainment of reductions in both HbA1c and
body weight compared with glimepiride at
Weeks 52 and 104, and was generally well
tolerated in patients with T2DM when used as
adjunctive therapy to metformin.
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